Published in J Clin Epidemiol on November 01, 1993
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
EU's new pharmacovigilance legislation: considerations for biosimilars. Drug Saf (2014) 2.12
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol (2009) 1.96
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol (2008) 1.69
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol (2010) 1.50
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One (2011) 1.45
Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ (2003) 1.42
Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology (2015) 1.30
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol (2009) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol (2008) 1.18
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci (2005) 1.12
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol (2012) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol (2014) 1.11
Acute liver failure including acetaminophen overdose. Med Clin North Am (2008) 1.10
Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol (2005) 1.09
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Drug-induced liver injury: present and future. Clin Mol Hepatol (2012) 1.06
Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. BMJ Case Rep (2009) 1.05
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol (2011) 1.04
Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. J Clin Transl Hepatol (2015) 1.03
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol (2007) 1.03
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01
Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int (2009) 1.00
Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol (2013) 0.99
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One (2012) 0.98
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol (2012) 0.97
Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord (2008) 0.97
Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis? J Clin Transl Hepatol (2013) 0.96
Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci (2012) 0.95
Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol (2007) 0.94
A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. Br J Clin Pharmacol (2010) 0.93
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol (2011) 0.93
Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci (2008) 0.92
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy Asthma Immunol Res (2015) 0.91
Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS One (2011) 0.91
Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf (2014) 0.89
Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol (2014) 0.89
Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol (2011) 0.88
Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf (2013) 0.88
Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci (2008) 0.87
Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch (2011) 0.87
Occupational hepatic disorders in Korea. J Korean Med Sci (2010) 0.87
Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol (2013) 0.87
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One (2013) 0.87
Causality assessment of cutaneous adverse drug reactions. Ann Dermatol (2011) 0.87
[Adverse drugs reactions: diagnosis and assessment]. Pathologe (2006) 0.86
Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig Dis Sci (2008) 0.86
N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Syst Rev (2015) 0.86
A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci (2015) 0.85
Drug-Induced Liver Injury Associated with Noni (Morinda citrifolia) Juice and Phenobarbital. Case Rep Gastroenterol (2013) 0.85
Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol (2016) 0.85
Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. Korean J Radiol (2014) 0.85
Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol (2015) 0.85
Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol (2012) 0.85
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer (2012) 0.85
A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther (2015) 0.85
Trastuzumab-induced hepatotoxicity: a case report. Breast Care (Basel) (2013) 0.85
Corticosteroid therapy in a case of severe cholestasic hepatitis associated with amoxicillin-clavulanate. J Med Toxicol (2010) 0.85
Liver physiology and liver diseases in the elderly. World J Gastroenterol (2013) 0.84
Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver (2016) 0.84
Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol (2010) 0.84
Acute liver failure after recommended doses of acetaminophen in patients with myopathies. Crit Care Med (2011) 0.83
Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs. Can J Gastroenterol (2006) 0.83
Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci (2015) 0.83
A Case of Drug-Induced Hepatitis due to Lenalidomide. Case Rep Gastroenterol (2011) 0.83
Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep (2015) 0.82
Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests. World J Hepatol (2013) 0.82
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci (2016) 0.82
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther (2010) 0.82
Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. Dig Dis Sci (2001) 0.82
Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. BMC Med (2015) 0.82
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci (2016) 0.81
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One (2014) 0.81
The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. Int J Mol Sci (2016) 0.81
The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges. Int J Mol Sci (2016) 0.81
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol (2014) 0.81
Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol (2012) 0.81
Safety of roxithromycin. Lancet (1992) 1.94
[Criteria for assessing granulocytic or platelet cytopenia caused by drugs. Results of consensus meetings]. Nouv Rev Fr Hematol (1987) 1.04
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin]. Ann Med Interne (Paris) (1974) 1.01
[Score of suspected drug-induced acute liver disorders. Presentation of an evaluation sheet]. Gastroenterol Clin Biol (1993) 0.80
[Drug-induced cutaneous photosensitivity. Results of a consensus meeting]. Therapie (1989) 0.80
[Takayasu's syndrome and lupus disease]. Ann Med Interne (Paris) (1970) 0.80
Absence of intrathecal synthesis of some interferon-alpha subtypes in bacterial meningitis. J Infect Dis (1992) 0.79
Articular cartilage atrophy in lower limb amputees. Arthritis Rheum (1982) 0.76
[Epiretinal membrane and photocoagulation with argon laser. Discussion of 3 cases]. Bull Soc Ophtalmol Fr (1989) 0.76
[Management of clinical or biological abnormalities during therapeutic trials]. Therapie (1989) 0.75
[Relationships between the thyroid and parathyroid]. Actual Endocrinol (Paris) (1973) 0.75
[Bilateral and recurrent corneal multiperforations caused by self-mutilation during an epileptic crisis]. Bull Soc Ophtalmol Fr (1987) 0.75
[Iodine 125 curietherapy of choroidal melanomas. Values of the technique and initial results]. J Fr Ophtalmol (1996) 0.75
[Fanconi's syndrome in adults (phospho-gluco-amino diabetes) and cancer]. Ann Med Interne (Paris) (1969) 0.75
[Not Available]. Rev Prat (1959) 0.75
[Consensus conference on definitions in drug monitoring]. Therapie (1988) 0.75
[Rheumatic anti-inflammatory agents and digestive intolerance. Preventive treatment with a weak bismuth subnitrate solution (Novismuth). Study of 172 cases]. Gaz Med Fr (1965) 0.75
[Secondary syphilis with osteolysis of skull bones]. Bull Soc Fr Dermatol Syphiligr (1969) 0.75
[The AIDS theme in psychopathologic productions]. Ann Med Psychol (Paris) (1988) 0.75
[Takayasu's disease and Horton's disease]. Coeur Med Interne (1967) 0.75
[International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group]. Therapie (1992) 0.75
[How to diagnose a cutaneous complication of a drug. Application to vascular purpura]. Ann Dermatol Venereol (1987) 0.75
[What therapeutic attitude to adopt in juvenile retinoschisis?]. Bull Soc Ophtalmol Fr (1986) 0.75
[Choroidal melanoma treated by protontherapy: anatomical and functional results at Strasbourg University Medical Center]. J Fr Ophtalmol (2013) 0.75
[Interstitial pneumopathies: criteria of drug side-effects. Results of consensus meetings]. Presse Med (1989) 0.75
[Drug-induced hemolytic anemia. Results of consensus conferences]. Therapie (1988) 0.75
[Choroidal detachment and surgery of retinal detachment. Discussion of its incidence and complications]. Bull Soc Ophtalmol Fr (1987) 0.75
[A survey on the somatic symptoms of couvade]. Ann Med Psychol (Paris) (1991) 0.75
[Neuropsychiatric forms of AIDS, apropos of some cases]. Ann Med Psychol (Paris) (1988) 0.75
Standardized coding is needed for reports of adverse drug reactions. BMJ (1996) 0.75